Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet HIV ◽

10.1016/s2352-3018(21)00071-0 ◽

2021 ◽

Vol 8 (7) ◽

pp. e397-e407

Author(s):

Onyema Ogbuagu ◽

Peter J Ruane ◽

Daniel Podzamczer ◽

Laura C Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Download Full-text

Longer-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Versus Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3772801 ◽

2021 ◽

Author(s):

Onyema Ogbuagu ◽

Peter J. Ruane ◽

Daniel Podzamczer ◽

Laura C. Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Download Full-text

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

10.1016/s0140-6736(20)31065-5 ◽

2020 ◽

Vol 396 (10246) ◽

pp. 239-254 ◽

Author(s):

Kenneth H Mayer ◽

Jean-Michel Molina ◽

Melanie A Thompson ◽

Peter L Anderson ◽

Karam C Mounzer ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis

Download Full-text

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

The Lancet HIV ◽

10.1016/s2352-3018(16)00024-2 ◽

2016 ◽

Vol 3 (4) ◽

pp. e158-e165 ◽

Author(s):

Joel E Gallant ◽

Eric S Daar ◽

François Raffi ◽

Cynthia Brinson ◽

Peter Ruane ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

10.1016/s0140-6736(15)60616-x ◽

2015 ◽

Vol 385 (9987) ◽

pp. 2606-2615 ◽

Author(s):

Paul E Sax ◽

David Wohl ◽

Michael T Yin ◽

Frank Post ◽

Edwin DeJesus ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Faculty Opinions recommendation of Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725442708.793509558 ◽

2015 ◽

Author(s):

Anthony Harries

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial

HIV Clinical Trials ◽

10.1080/15284336.2017.1291867 ◽

2017 ◽

Vol 18 (3) ◽

pp. 135-140 ◽

Author(s):

Frank A. Post ◽

Yazdan Yazdanpanah ◽

Gabriel Schembri ◽

Adriano Lazzarin ◽

Jacques Reynes ◽

...

Keyword(s):

Subgroup Analysis ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Faculty Opinions recommendation of Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954439.793460355 ◽

2012 ◽

Author(s):

Kiat Ruxrungtham ◽

Wirach Maek-a-nantawat

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Initial Treatment ◽

Phase 3 ◽

Double Blind ◽

Download Full-text

Spine Treatment Appraisal Report (STAR): Does Riluzole Improve Outcomes in Patients Undergoing Decompression Surgery for Degenerative Cervical Myelopathy?

Global Spine Journal ◽

10.1177/2192568221997401 ◽

2021 ◽

pp. 219256822199740

Author(s):

Joseph R. Dettori

Keyword(s):

Cervical Myelopathy ◽

Decompressive Surgery ◽

Decompression Surgery ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Degenerative Cervical Myelopathy

Fehlings MG, Badhiwala JH, Ahn H, et al. Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Neurol. 2020.

Download Full-text

Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet Neurology ◽

10.1016/s1474-4422(20)30407-5 ◽

2020 ◽

Author(s):

Michael G Fehlings ◽

Jetan H Badhiwala ◽

Henry Ahn ◽

H Francis Farhadi ◽

Christopher I Shaffrey ◽

...

Keyword(s):

Cervical Myelopathy ◽

Decompressive Surgery ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Degenerative Cervical Myelopathy

Download Full-text

THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies

10.1136/annrheumdis-2017-eular.1839 ◽

2017 ◽

Author(s):

TK Kvien ◽

A Deodhar ◽

L Gossec ◽

PG Conaghan ◽

V Strand ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Long Term Results ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Sustained Reduction

Download Full-text